抗體介導的排斥反應市場－全球、區域和國家層面的分析與預測（2025-2035 年）

抗體介導的排斥反應（AMR）是一種器官移植排斥反應，其中受體的免疫系統產生抗體攻擊移植的器官。

這種反應不同於細胞介導的排斥反應，後者是指T細胞攻擊移植器官。抗體介導的排斥反應則涉及抗體的形成，這些抗體能夠辨識並結合主要存在於移植器官血管上的外來分子（抗原）。

受多種關鍵因素驅動，全球抗體介導排斥反應市場正顯著擴張。其中一個關鍵促進因素是全球器官移植手術數量的不斷成長，因為人口老化和器官衰竭病例的增加導致移植需求持續上升。這使得預防、診斷和治療抗體介導排斥反應的需求顯著增加。分子生物學和免疫學的進步也促進了人們對抗體介導排斥反應的理解和診斷，從而推動了標靶治療的開發，以更有效地控制移植排斥反應。

此外，供體特異性抗體（DSA）檢測和補體依賴性細胞毒性試驗等診斷測試的普及和準確性不斷提高，使得抗體介導的排斥反應能夠更早被發現，從而改善臨床療效並提高患者生存率。基於基因和免疫學特徵客製化治療方法的精準醫療的日益普及也是推動市場成長的因素之一。這將使抗體介導的排斥反應的治療更加個人化和有效，有望提高移植成功率和患者生活品質。

然而，抗體介導的排斥反應市場也面臨一些可能阻礙其成長的挑戰。先進診斷工具和治療方法的高成本可能成為一大障礙，尤其是在醫療資源有限的中低收入國家。抗體介導的排斥反應的治療複雜性需要專業知識，這可能會限制醫療基礎設施低度開發地區獲得治療的機會。此外，儘管治療方案眾多，但抗體介導的排斥反應通常是一種慢性疾病，可能需要長期管理，這會對患者和醫療系統造成持續的經濟負擔。

儘管面臨這些挑戰，賽諾菲、漢莎生物製藥和泰拉瑞斯治療公司等主要企業仍致力於研發新的治療方案。他們正在探索基因療法、單株抗體和其他新型生物製藥的潛力，以更有效地靶向抗體介導排斥反應的根本原因。這不僅推動了競爭和創新，也促使各公司改進現有治療方法的安全性和有效性。

隨著抗體介導排斥反應市場的不斷發展，預計以下幾個趨勢將影響其未來的成長。機器學習和人工智慧在診斷和治療方案製定中的日益普及，將使介入更加精準及時。個人化醫療的興起，以及器官保存和移植技術的進步，將進一步最佳化移植手術患者的預後。此外，醫護人員和患者對抗體介導排斥反應的教育和意識提升的提高，將有助於早期發現和積極管理疾病。

本報告檢視了全球抗體介導排斥市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、市場規模趨勢和預測、按各個細分市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

第1章 全球抗體介導排斥反應市場：產業展望

• 市場趨勢
• 法律規範
• 流行病學情景
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機遇

2. 全球抗體介導排斥反應市場（依地區分類）

• 北美洲
• 歐洲
• 亞太地區
  • 主要發現
  • 市場動態
  • 市場規模及預測

第3章 全球抗體介導排斥反應市場：競爭格局與公司概況

• 關鍵發展和策略
  • M&A
  • 協同活動
  • 業務拓展及資金籌措
  • 產品上市及核准
  • 其他活動
• 公司簡介
  • Hansa Biopharma
  • Sanofi
  • Alexion

第4章調查方法

Global Antibody-Mediated Rejection Market, Analysis and Forecast: 2025-2035

Antibody-mediated rejection (AMR) is a type of organ transplant rejection in which the recipient's immune system produces antibodies that attack the transplanted organ. This response is different from cellular rejection, where T-cells attack the transplant. antibody-mediated rejection primarily involves the formation of antibodies that recognize and bind to foreign molecules (antigens) present on the blood vessels of the transplanted organ.

The global antibody-mediated rejection market is expanding significantly, fueled by several key factors. One of the main drivers is the growing number of organ transplant procedures worldwide, as the demand for transplants continues to rise, driven by an aging population and an increase in organ failure cases. This has created a substantial need for antibody-mediated rejection prevention, diagnosis, and treatment options. Advances in molecular biology and immunology are also facilitating better understanding and diagnosis of antibody-mediated rejection, promoting the development of targeted therapies that offer more effective management of transplant rejection.

Moreover, the increasing availability and accuracy of diagnostic tests, such as donor-specific antibody (DSA) detection and complement-dependent cytotoxicity assays, are helping to identify antibody-mediated rejection earlier, leading to better clinical outcomes and improved patient survival rates. The rising adoption of precision medicine, which tailors treatments based on genetic and immunological profiling, is another factor contributing to the market growth. This allows for more personalized and effective treatments for antibody-mediated rejection, improving transplant success rates and patient quality of life.

However, the antibody-mediated rejection market faces certain challenges that could hinder its growth. The high cost of advanced diagnostic tools and treatments can be a barrier, particularly in low- and middle-income countries with limited healthcare resources. The complexity of managing antibody-mediated rejection also requires specialized expertise, which can limit access to care in regions with underdeveloped healthcare infrastructure. Additionally, while many treatment options exist, antibody-mediated rejection is often a chronic condition that may require long-term management, placing a continuous financial burden on patients and healthcare systems alike.

Despite these challenges, leading players in the antibody-mediated rejection market, such as Sanofi, Hansa Biopharma, and Talaris Therapeutics. are focusing on research and development of new therapeutic options. Companies are exploring the potential of gene therapies, monoclonal antibodies, and other novel biologics to target the underlying causes of antibody-mediated rejection more effectively. This has spurred increased competition and innovation, with companies also striving to improve the safety and efficacy profiles of current treatments.

As the antibody-mediated rejection market evolves, several trends are expected to shape its future growth. The increasing use of machine learning and artificial intelligence in both diagnostics and treatment planning will allow for more accurate and timely intervention. The growing trend toward personalized medicine, combined with advances in organ preservation and transplant techniques, will further optimize outcomes for patients undergoing transplant procedures. In addition, heightened awareness and the development of educational initiatives for both healthcare providers and patients will help in early detection and proactive management of antibody-mediated rejection.

In conclusion, the antibody-mediated rejection market is poised for significant growth, driven by advancements in diagnostics, treatment options, and personalized medicine. With the increasing number of organ transplant procedures and the growing recognition of antibody-mediated rejection impact on patient outcomes, stakeholders in the healthcare industry, including pharmaceutical companies, medical device manufacturers, and healthcare providers, will play a pivotal role in addressing the challenges and meeting the demand for effective antibody-mediated rejection management. The continued evolution of this market will improve the quality of life for transplant recipients and ensure better transplant success rates worldwide.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Antibody-mediated Rejection Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Scenario
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Antibody-mediated Rejection Market, by Region, $Million, 2024-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Antibody-mediated Rejection Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Antibody-mediated Rejection Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Antibody-mediated Rejection Market, by Country
      • 2.3.3.1.1 Japan

3. Global Antibody-mediated Rejection Market: Competitive Landscape and Company Profiles

• 3.1 Key Development and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Hansa Biopharma
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Target Customers/End-Users
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Sanofi
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Target Customers/End-Users
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Alexion
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Target Customers/End-Users
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Antibody-mediated Rejection Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Antibody-mediated Rejection Market, 2024 and 2035
• Figure: Global Antibody-mediated Rejection Market Key Trends, Impact Analysis
• Figure: North America Antibody-mediated Rejection Market, $Million, 2024-2035
• Figure: Europe Antibody-mediated Rejection Market, $Million, 2024-2035
• Figure: Asia-Pacific Antibody-mediated Rejection Market, $Million, 2024-2035

List of Tables

• Table: Market Snapshot
• Table: Market Dynamics
• Table: Global Antibody-mediated Rejection Market (by Region), $Million, 2024-2035